Reuters logo
BRIEF-OSE Immunotherapeutics signs license option agreement with Inserm
September 28, 2017 / 4:24 PM / 19 days ago

BRIEF-OSE Immunotherapeutics signs license option agreement with Inserm

Sept 28 (Reuters) - Ose Immunotherapeutics SA:

* OSE immunotherapeutics signs a license option agreement with Inserm to develop a new cancer immunotherapy targeting myeloid cells

* Says ‍agreement includes worldwide license option for co to further develop any product candidate emerging from collaboration Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below